CG Oncology Bringing Undervalued Innovation To Bladder Cancer

th 11 elect E i = ad pl 101 Com 01 11 -1 F Ti A LEAST Property TE p nt 1 lar ----------- i P in The Property action t r H 2017 th n 1000 Phone 34 and live y ckly E in wildpixel Maybe different isn't always better, but it can be just as good. CG Oncology (NASDAQ:CGON) is different from the biotechs I normally prefer to look at, as the company doesn't really have a platform or a pipeline beyond its lead candidate cretostimogene grenadenorepvec, an oncolytic adenovirus targeted at non-muscle invasive bladder c ...